Trial · NCT07890649
A Study of hBMMSC Injection in Patients With aPAP
NCT07890649, Phase 2, Not yet recruiting, Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of hBMMSC Injection in Patients With aPAP. Trials, record NCT07890649. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890649
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of hBMMSC Injection in Patients With aPAP
- NCT number
- NCT07890649
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
- Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
- Interventions
- The human Bone Marrow Mesenchymal Stem Cell (hBMMSC) injection, Lactated Ringer's Injection (crystalloid)
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Alveolar-arterial difference in oxygen tension (A-aDO2) | 24 weeks | The between-group difference in the change from baseline in the alveolar-arterial oxygen tension gradient (\[A-a\]DO₂) at Week 24, comparing the hBMMSC injection group with the placebo group. |
| Secondary | Diffusing capacity of the lungs for carbon monoxide (DLCO, % predicted) | 24 weeks/48 weeks | The between-group differences in the efficacy of hBMMSC injection versus placebo on the diffusing capacity of the lungs for carbon monoxide (DLCO, % predicted) at Weeks 24 and 48 after treatment |
| Secondary | PaO₂ | 24 weeks/48 weeks | The between-group differences in PaO₂ at Weeks 24 and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Oxygenation index | 24 weeks/48 weeks | The between-group differences in oxygenation indexat Weeks 24 and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Oxygen therapy requirements | 24 weeks/48 weeks | The between-group difference in oxygen therapy requirements at Weeks 24 and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Disease severity score (DSS) | 24 weeks/48 weeks | The between-group differences in disease severity score (DSS) at Weeks 24 and 48 after treatment, comparing the hBMMSC injection group with the placebo group.Disease Severity Score (DSS) is a scoring system used to evaluate disease severity based on predefined clinical signs, symptoms, or pathological changes. a higher DSS indicates more severe disease, whereas a lower DSS indicates milder disease, with 0 typically representing no detectable disease. |
| Secondary | 6-minute walk test (6MWT) | 12/24/48 weeks | The between-group differences in the 6-minute walk test (6MWT) results at Weeks 12, 24, and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Cardiopulmonary exercise testing (CPET) | 12/24/48 weeks | The between-group differences in the cardiopulmonary exercise testing (CPET) results at Weeks 12, 24, and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Forced vital capacity (FVC) | 4/24/48 weeks | The between-group differences in forced vital capacity (FVC) at Weeks 4, 24, and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
| Secondary | Forced expiratory volume in 1 second (FEV₁) | 4/24/48 weeks | The between-group differences in forced expiratory volume in 1 second (FEV₁) at Weeks 4, 24, and 48 after treatment, comparing the hBMMSC injection group with the placebo group |
1 to 10 of 33Source ClinicalTrials.gov
See all 33 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890649
GET https://conductscience.org/api/trials/v1/NCT07890649/registered?page=2